Skip to content
Open access

Association Between Circulating CD107a+ Natural Killer Cells and Clinical Nodal Stage in Early Breast Cancer: An Exploratory Prospective Biomarker Cohort Study

Nov 2026 · Cancers · 0 citations · 47 references

Abstract

Objectives: Minimally invasive biomarkers for risk stratification in early breast cancer are lacking. We examined whether pretreatment circulating natural killer (NK)-cell subsets, specifically CD107a+ NK cells, are associated with clinicopathological features and outcomes of early breast cancer and whether tumor transcriptomes reflect NK-cell subset levels. Materials and Methods: Circulating NK-cell subsets were quantified by flow cytometry in 94 patients with stages I–III breast cancer prior to surgery and systemic therapy (median follow-up 42.6 months; 10 relapses, 7 deaths). Associations across 12 immune subsets were corrected for multiple comparisons (Benjamini–Hochberg false-discovery rate, FDR). Matched tumor RNA-sequencing (n = 25) informed a weighted CD107a-associated tumor-expression score that was examined for an association with survival in TCGA-BRCA (n = 1096). Results: Low circulating CD107a+ NK-cell levels were associated with clinically node-positive disease (cN1–3, raw p = 0.048), increased relapse rate (p = 0.003), and death (p < 0.001). Of 96 association tests, only the CD107a+ NK-cell level and overall survival approached significance after FDR correction (q = 0.096); the clinical nodal-stage association did not survive correction (q = 0.93). Exploratory multivariable models were unstable given the few events. Immunoglobulin lambda genes, the dominant contributors to the tumor-expression score, separated survival in TCGA-BRCA (log-rank p = 0.0096), confirming a tumor signature rather than validating circulating CD107a+ NK cells as a biomarker. Conclusions: Low circulating CD107a+ NK cells were associated with, but do not yet establish, higher-risk early breast cancer. The findings of the present study are hypothesis-generating and do not confirm biomarker status of CD107a+ NK cells in early breast cancer. Prospective, adequately powered, externally validated studies are required before prognostic or therapeutic use.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.